Total Brain (ASX:TTB) - Chairman, Evian Gordon
Chairman, Evian Gordon
Source: Total Brain
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Total Brain (TTB) signs a three year contract to provide mental health software to US global specialty materials company, Eastman
  • The renewable contract with Eastman will see Total Brain roll out its product to around 10,500 American employees and their spouses
  • Total Brain says this deal represents $250,000 in annual recurring revenue for the company
  • Total Brain is trading flat at 31 cents at 11:35 am AEST

Total Brain (TTB) has signed a three year contract to provide mental health software to US global specialty materials company, Eastman.

Total Brain offers the world’s first mental health self-monitoring and self-care platform, powered by a standardised brain database.

The app allows users to practise short and medium-term self-care, access professional care when needed and measure treatment impact over time, while focusing on breathing, positive psychology, meditation and brain training.  

 The company says its platform has assisted more than one million registered users to scientifically measure and optimise their brain capacities, while managing the risk of common mental health conditions.

The renewable contract with Eastman will see Total Brain roll out its product to around 10,500 American employees and their spouses or domestic partners, representing $250,000 in annual recurring revenue for the company.

The platform is said to benefit employers and insurers by reducing healthcare costs, while assisting productivity improvements in the workplace.

Total Brain says this is an important milestone for the company and it offers significant validation for market demand for scalable, tech-enabled mental health solutions.

Total Brain was trading flat at 31 cents at 11:35 am AEST.

TTB by the numbers
More From The Market Online

PharmAust CEO’s sayanora triggers stock plunge

Clinical-stage biotechnology company, PharmAust shares plunged 24 per cent so this morning, following the resignation of…

Emyria locks in $2.3M to progress MDMA research – with Chair adding $0.3M

WA-based and ASX-listed Emyria is seeking to further research using MDMA to treat PTSD. The chair…

Genetic Signatures wins TGA greenlight for flu test device – just before winter

Genetic Signatures (ASX:GSS) shares were down -1.45% to 68cps on Monday, even as the company reported…

PYC Therapeutics takes Polycystic Kidney Disease drug to human trials

PYC Therapeutics takes its latest drug for Polycystic Kidney Disease, characterized by the formation of cysts…